About this item
Product details
Wegovy (semaglutide) is a prescription GLP‑1 receptor agonist indicated for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia) . Administered once weekly subcutaneously, it works by reducing appetite and slowing gastric emptying . Wegovy is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke) in adults with established cardiovascular disease and either obesity or overweight . Clinically Proven Weight Loss: The 2.4 mg maintenance dose produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 0.5 mg dose helping to build tolerance during the initial titration phase. Reduces Cardiovascular Risk: The SELECT trial demonstrated that semaglutide 2.4 mg reduced the relative risk for major adverse cardiovascular events by 20% compared with placebo in adults with established cardiovascular disease and BMI ≥27 kg/m² Convenient Once‑Weekly Dosing: Inject subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals Composition Each prefilled pen contains 2 mg semaglutide in 1.5 mL (1.34mg/mL) Directions for Use Use as prescribed by the physician.
- Medicines
- 1 x 1.5mL pen & 4 disposable needles
- 1 variant
- Protected Dastak checkout
Know before you buy
Specifications
- Department
- Health
- Subcategory
- Medicines
- Brand
- Novo Nordisk
- SKU
- 05712249133030
- Variant
- 1 x 1.5mL pen & 4 disposable needles
- Tags
- Diabetes, Heart, Heart Support, Insulin, Medicine, Semaglutide, Type 2 Diabetes, Weight Loss
- Condition
- New
Customer feedback
Ratings & reviews
For help with a purchase, open your orders or contact Dastak support.
